JP6009457B2 - ポリマー−デスエチルスニチニブコンジュゲート - Google Patents

ポリマー−デスエチルスニチニブコンジュゲート Download PDF

Info

Publication number
JP6009457B2
JP6009457B2 JP2013546457A JP2013546457A JP6009457B2 JP 6009457 B2 JP6009457 B2 JP 6009457B2 JP 2013546457 A JP2013546457 A JP 2013546457A JP 2013546457 A JP2013546457 A JP 2013546457A JP 6009457 B2 JP6009457 B2 JP 6009457B2
Authority
JP
Japan
Prior art keywords
ethyl
compound
polymer
carboxamido
daltons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013546457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014501765A5 (enExample
JP2014501765A (ja
Inventor
アントニ コズロウスキ,
アントニ コズロウスキ,
ショーン エム. カルバートソン,
ショーン エム. カルバートソン,
シャオミン シェン,
シャオミン シェン,
サミュエル ピー. マクマナス,
サミュエル ピー. マクマナス,
マーク エー. ウィルソン,
マーク エー. ウィルソン,
Original Assignee
ネクター セラピューティクス
ネクター セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネクター セラピューティクス, ネクター セラピューティクス filed Critical ネクター セラピューティクス
Publication of JP2014501765A publication Critical patent/JP2014501765A/ja
Publication of JP2014501765A5 publication Critical patent/JP2014501765A5/ja
Application granted granted Critical
Publication of JP6009457B2 publication Critical patent/JP6009457B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polyethers (AREA)
JP2013546457A 2010-12-23 2011-12-23 ポリマー−デスエチルスニチニブコンジュゲート Active JP6009457B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426893P 2010-12-23 2010-12-23
US61/426,893 2010-12-23
PCT/US2011/067240 WO2012088522A1 (en) 2010-12-23 2011-12-23 Polymer-des-ethyl sunitinib conjugates

Publications (3)

Publication Number Publication Date
JP2014501765A JP2014501765A (ja) 2014-01-23
JP2014501765A5 JP2014501765A5 (enExample) 2014-12-25
JP6009457B2 true JP6009457B2 (ja) 2016-10-19

Family

ID=45496320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013546457A Active JP6009457B2 (ja) 2010-12-23 2011-12-23 ポリマー−デスエチルスニチニブコンジュゲート

Country Status (4)

Country Link
US (2) US10220020B2 (enExample)
EP (1) EP2654797B1 (enExample)
JP (1) JP6009457B2 (enExample)
WO (1) WO2012088522A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827326B2 (en) 2010-12-23 2017-11-28 Nektar Therapeutics Polymer-sunitinib conjugates
WO2012088506A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-semaxanib moiety conjugates
EP2654797B1 (en) 2010-12-23 2017-11-08 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
DK3039424T3 (da) 2013-08-28 2020-08-31 Crown Bioscience Inc Taicang Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse
ES2910659T3 (es) * 2014-12-04 2022-05-13 Delta Fly Pharma Inc Nuevo derivado de PEG
MA42953A (fr) 2015-09-22 2018-08-01 Graybug Vision Inc Composés et compositions pour le traitement de troubles oculaires
WO2018175922A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
CN111995513B (zh) * 2019-05-27 2022-11-01 天津键凯科技有限公司 一种9-羟甲基-芴二酸的制备方法
GB201916046D0 (en) * 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
WO2022103983A2 (en) * 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
MXPA02006263A (es) 1999-12-22 2004-02-26 Sugen Inc Metodos de modulacion de la funcion de la cinasa de tirosina c-kit de la proteina con compuestos de indolinona.
BRPI0117360B8 (pt) 2000-02-15 2021-07-06 Upjohn Co inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
EP1299355A2 (en) 2000-05-02 2003-04-09 Sugen, Inc. (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
CA2466027C (en) 2001-11-07 2013-01-08 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
US7053144B1 (en) 2002-06-13 2006-05-30 Cmi Rubber Company, Inc. High density rubber compounds
US20050079155A1 (en) 2003-03-20 2005-04-14 Xencor, Inc. Generating protein pro-drugs using reversible PPG linkages
US7887789B2 (en) 2003-05-23 2011-02-15 Nektar Therapeutics Polymer derivatives having particular atom arrangements
JP5632119B2 (ja) 2003-09-17 2014-11-26 ウェルズ ファーゴ バンク ナショナル アソシエイション 多分岐ポリマーのプロドラッグ
WO2005107815A2 (en) 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Polymer derivatives comprising an imide branching point
WO2005108463A2 (en) 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Branched polyethylen glycol derivates comprising an acetal or ketal branching point
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
HUE025208T2 (en) 2005-06-16 2016-03-29 Nektar Therapeutics Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
JP5312050B2 (ja) 2006-02-21 2013-10-09 ネクター セラピューティクス 分割型の分解性重合体とそれから生成される複合体
US20080044438A1 (en) 2006-03-17 2008-02-21 Ostroff Gary R Yeast Cell Particles As Oral Delivery Vehicles For Antigens
CA2671676C (en) 2006-12-27 2014-04-22 Baxter Healthcare Sa Von willebrand factor-and factor viii-polymer conjugates having a releasable linkage
AU2008331868B2 (en) 2007-11-28 2015-02-12 Nektar Therapeutics Oligomer-tricyclic conjugates
EP2254601B1 (en) 2008-02-08 2019-05-29 Nektar Therapeutics Oligomer-cannabinoid conjugates
CN101998866A (zh) 2008-04-11 2011-03-30 尼克塔治疗公司 低聚物-芳氧基-取代的丙胺共轭物
US8658149B2 (en) 2008-05-22 2014-02-25 Ramot At Tel-Aviv University Ltd. Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
US20120052041A1 (en) * 2009-02-04 2012-03-01 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
WO2010120387A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
US8816077B2 (en) 2009-04-17 2014-08-26 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
EP2654797B1 (en) 2010-12-23 2017-11-08 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
US9827326B2 (en) 2010-12-23 2017-11-28 Nektar Therapeutics Polymer-sunitinib conjugates
US20140331425A1 (en) 2013-05-09 2014-11-13 DeAndre Charles Baker Sqeeky kleen toilet brush

Also Published As

Publication number Publication date
US20140039030A1 (en) 2014-02-06
EP2654797A1 (en) 2013-10-30
EP2654797B1 (en) 2017-11-08
US11406618B2 (en) 2022-08-09
US20190142798A1 (en) 2019-05-16
US10220020B2 (en) 2019-03-05
JP2014501765A (ja) 2014-01-23
WO2012088522A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
JP6009457B2 (ja) ポリマー−デスエチルスニチニブコンジュゲート
JP6002149B2 (ja) ポリマー−スニチニブコンジュゲート
CA2947895C (en) Nanoparticle drug conjugates
US11007270B2 (en) Polymer-semaxanib moiety conjugates
US9095622B2 (en) Oligomer-protein tyrosine kinase inhibitor conjugates
TW201801751A (zh) 靶向構建體及其製劑
Kozlowski et al. Polymer-des-ethyl sunitinib conjugates
JP5792175B2 (ja) オリゴマー−カルシミメティクスコンジュゲートおよび関連化合物
JP6265998B2 (ja) オリゴマー含有ベンズアミド系化合物
HK1236384B (en) Nanoparticle drug conjugates
HK1236384A1 (en) Nanoparticle drug conjugates

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151118

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20151228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160810

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160907

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160914

R150 Certificate of patent or registration of utility model

Ref document number: 6009457

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250